May 11-14, 2026
Hynes Convention CenterBoston, MAKey Sessions
Kristy Wood, PhD
Realizing the Promise of CRISPR Therapeutics
Intellia Therapeutics
Hiroaki Suga, PhD
RaPID Display and Selection of Pseudo-natural Products
University of Tokyo
Lotte Bjerre Knudsen, PhD
The Science Behind the GLP-1 Medicines: A Historic View and Future Outlook
Novo Nordisk A/S
Sam Tsimikas, MD
Clinical Update on Oligonucleotides for Cardiovascular Disease
Ionis Pharmaceuticals
Mike Flanagan, PhD
Antibody Oligonucleotide Conjugates (AOCs): RNA Delivery Beyond the Liver
Avidity Biosciences
Muthiah (Mano) Manoharan, PhD
“I Love Conjugates”: The GalNAc Revolution and Its Impact on Oligonucleotide Therapeutic Development
Alnylam Pharmaceuticals
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 1 Keynote Sessions (May 20)
keyboard_arrow_leftSearch & Filter
search
Streams
Main Conference - Day 1 Keynote Sessions (May 20)
search
Streams
6:30am - 7:30am
Registration
Breakfast Spotlight Presentations
Showing 3 of 3 Streams
Breakfast Spotlight Presentations 1
Breakfast Spotlight Presentations 2
Breakfast Spotlight Presentations 3
7:30am - 8:00am
Synthetic Peptide CMC Development and Experiences
- Susan Li, PhD - Peptide Chief Scientist, Asymchem
Showing 1 of 1 Streams
Keynote and Plenary Session
8:10am - 8:15am
Chairperson’s Remarks: Keynote Day 1
- Mimoun Ayoub, PhD - Senior VP, Global Head of Peptide and Oligonucleotide Platforms, CordenPharma International
8:15am - 9:00am
The Science Behind the GLP-1 Medicines: A Historic View and Future Outlook
- Lotte Bjerre Knudsen, PhD - Chief Scientific Advisor & Head of GLP-1 CoE, Novo Nordisk A/S
9:00am - 9:45am
“I Love Conjugates”: The GalNAc Revolution and Its Impact on Oligonucleotide Therapeutic Development
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
9:45am - 10:15am
Networking Refreshment Break
Morning Keynote Session
Showing 1 of 1 Streams
Keynote and Plenary Session
10:15am - 11:00am
Realizing the Promise of CRISPR Therapeutics
- Kristy Wood, PhD - SVP, Technical Operations, Intellia Therapeutics
11:00am - 11:45am
Oligonucleotide Therapeutics: Current Challenges and Opportunities
- David Corey, PhD - Professor of Pharmacology and Biochemistry, UT Southwestern; Past President, OTS
11:45am - 12:05pm
Transition to Spotlight Presentation/Panel Luncheons
Spotlight Presentation Luncheons
Showing 6 of 6 Streams
Spotlight Presentation Luncheon 1
Spotlight Presentation Luncheon 2
Spotlight Presentation Luncheon 3
Spotlight Presentation Luncheon 4
Spotlight Luncheon Presentation 5
Spotlight Presentation Luncheon 6
12:05pm - 12:35pm
Biodegradable Lipid Nanoparticles with Tunable Immunogenicity
The immunogenicity of ionizable lipids is a significant issue in applications such as gene editing or mRNA therapeutics. We have developed a novel chemical family of biodegradable lipids (COATSOME® SS Series) that exhibit exceptional stability in the circulating state and only break down when triggered by specific stimuli present in the cytosol. We will present further data on the cytokine profile, toxicity, and efficacy of COATSOME® SS Series in multiple animal models.
- Syed Reza, MD, PhD - Scientific and Sales Consultant, NOF Corporation
12:05pm - 12:35pm
Advancing RNA Vaccines and Therapeutics: Cutting-edge Innovations in mRNA Manufacturing
- Kevin Ou - Director, Product Strategy & Management - mRNA LNP, Aldevron
12:05pm - 12:35pm
Advancing Sustainability in the Oligonucleotides Industry: Strategies for Environmental Responsibility and Innovation
- Prasad Panzade, PhD - Vice President, Research and Development, Nitto Avecia
12:05pm - 12:35pm
Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments
- Arne Berthelmann - Senior Director Oligonucleotide R&D, Bachem AG
12:05pm - 12:35pm
Chromatographic Tools for the Bioanalysis of Oligonucleotide Therapeutics
- Corin Perrin - Analytical Development Manager, Axolabs
- Philipp Hadwiger - Vice President, Head of R&D, Axolabs
12:35pm - 12:55pm
Short Networking Break
Afternoon Keynote Session
Showing 1 of 1 Streams
Keynote and Plenary Session
12:55pm - 1:00pm
Chairperson’s Remarks: Keynote Day 1
- Mimoun Ayoub, PhD - Senior VP, Global Head of Peptide and Oligonucleotide Platforms, CordenPharma International
1:00pm - 1:45pm
Clinical Update on Oligonucleotides for Cardiovascular Disease
- Sam Tsimikas, MD - Senior Vice President of Global Cardiovascular Development, Ionis Pharmaceuticals
1:45pm - 2:30pm
Antibody Oligonucleotide Conjugates (AOCs): RNA Delivery Beyond the Liver
- Mike Flanagan, PhD - Chief Scientific Officer, Avidity Biosciences
2:30pm - 3:30pm
Grand Opening of Poster and Exhibit Hall and Networking Refreshment Break
Showing 1 of 1 Streams
Keynote and Plenary Session
3:30pm - 4:15pm
RaPID Display and Selection of Pseudo-natural Products
This lecture discusses a new development of display format for the discovery of pseudo-natural products against intracellular targets of protein. The technology enables us to access unexplored chemical space with cell membrane permeability of macrocycles.
- Hiroaki Suga, PhD - Professor of Chemistry, School of Science, University of Tokyo
4:15pm - 5:00pm
Panel Discussion: Addressing the Challenges of Bringing New Therapeutic Modalities to Market: Technical and Regulatory Considerations
- John Zuris, PhD - Director of Delivery and Editing Technologies, Editas Medicine
- Melissa Bonner, PhD - Chief Scientific Officer, nChroma Bio
- Manmohan Singh, PhD - Chief Technology Officer, Beam Therapeutics
- Tyler Goodwin, PhD - Head of Delivery Technologies, Tune Therapeutics
- Priya Karmali, PhD - Chief Technology Officer, Capstan Therapeutics
5:00pm - 6:30pm
Networking Reception in Poster and Exhibit Halls
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams